New vaccine aims to train immune system to fight tough bladder cancer
NCT ID NCT05843448
Summary
This early-stage study is testing whether a new vaccine (IO102-IO103) combined with an existing immunotherapy drug (pembrolizumab) is safe and effective for patients with high-risk bladder cancer that hasn't responded to standard BCG treatment. The vaccine is designed to teach the body's immune system to better recognize and attack bladder cancer cells. Researchers will enroll about 30 patients to check for side effects and see if the combination helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 0A BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.